idw – Informationsdienst Wissenschaft
Nachrichten, Termine, Experten
Nachrichten, Termine, Experten
Vancomycin-resistant Enterococcus faecium (VRE) is among the most concerning antibiotic-resistant pathogens, as treatment options are severely limited. The resistance is due to the VanA or VanB enzyme complexes, which render vancomycin ineffective. However, VanB is often not reliably detected in standard diagnostic susceptibility tests, which can lead to ineffective therapies and the further spread of VRE. A researcher team is collaborating with a Belgian industry partner to develop an antibody-based rapid VRE test capable of reliably detecting the expression of VanA and VanB.
Enterococcus faecium is a bacterium that is naturally resistant to many common antibiotics. Particularly in vulnerable patient groups, such as immunocompromised individuals, the bacterium can cause infections that are difficult to treat and therefore poses a significant problem as a nosocomial pathogen. Vancomycin-resistant Enterococcus faecium (VRE) is among the most concerning antibiotic-resistant pathogens, as treatment options are severely limited. The resistance is due to the VanA or VanB enzyme complexes, which render vancomycin ineffective. However, VanB is often not reliably detected in standard diagnostic susceptibility tests, which can lead to ineffective therapies and the further spread of VRE.
The team led by Dr. Alexander Klimka, a researcher at the German Center for Infection Research (DZIF) from the Institute of Medical Microbiology, Immunology and Hygiene (IMMIH), is collaborating with Dr. Paul Higgins (IMMIH and DZIF) and a Belgian industry partner to develop an antibody-based rapid VRE test capable of reliably detecting the expression of VanA and VanB. The prototype of this rapid VRE test will then be evaluated using various clinical isolates and an in vitro intestinal model developed by Dr. Thomas Fließwasser (University Hospital Bonn), with the aim of bringing it to market in collaboration with the industry partner. “Our goal is to develop a rapid test that reliably detects both resistance mechanisms and can be easily integrated into everyday diagnostic practice,” says Dr. Alexander Klimka. To this end, Dr. Tamara Rügamer, senior physician at IMMIH, will conduct a clinical study to test whether the test can be integrated into the workflow of a university diagnostic laboratory and thereby contribute to a significantly simplified, safe, and ultimately more cost-effective diagnosis of VRE.
The University Hospital Cologne and the DZIF can draw on relevant experience in joint, translational test development. Dr. Alexander Klimka, Dr. Paul Higgins, and other IMMIH staff, together with the Belgian industry partner, have already successfully brought two rapid tests for the detection of carbapenemase-resistant Acinetobacter baumannii to market (OXA-23 K-SeT, 2018, and RESIST-ACINETO, 2022).
Dr. Alexander Klimka
University of Cologne
aklimka@uni-koeln.de
https://www.dzif.de/en/development-rapid-test-diagnosing-hard-treat-vre-bacteria DZIF press release with picture
Criteria of this press release:
Business and commerce, Journalists, Scientists and scholars
Medicine, Nutrition / healthcare / nursing
transregional, national
Research projects
English
You can combine search terms with and, or and/or not, e.g. Philo not logy.
You can use brackets to separate combinations from each other, e.g. (Philo not logy) or (Psycho and logy).
Coherent groups of words will be located as complete phrases if you put them into quotation marks, e.g. “Federal Republic of Germany”.
You can also use the advanced search without entering search terms. It will then follow the criteria you have selected (e.g. country or subject area).
If you have not selected any criteria in a given category, the entire category will be searched (e.g. all subject areas or all countries).
